These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9879991)

  • 21. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C; Mulligan LM
    Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
    Segouffin-Cariou C; Billaud M
    J Biol Chem; 2000 Feb; 275(5):3568-76. PubMed ID: 10652352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Putting the bits and pieces of the RET proto-oncogene puzzle together.
    Gagel RF
    Bone; 1995 Aug; 17(2 Suppl):13S-16S. PubMed ID: 8579892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation.
    Decker RA; Peacock ML; Watson P
    Hum Mol Genet; 1998 Jan; 7(1):129-34. PubMed ID: 9384613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
    Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
    EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
    Kjaer S; Kurokawa K; Perrinjaquet M; Abrescia C; Ibáñez CF
    Oncogene; 2006 Nov; 25(53):7086-95. PubMed ID: 16732321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.
    Asai N; Iwashita T; Matsuyama M; Takahashi M
    Mol Cell Biol; 1995 Mar; 15(3):1613-9. PubMed ID: 7532281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RET in human development and oncogenesis.
    Edery P; Eng C; Munnich A; Lyonnet S
    Bioessays; 1997 May; 19(5):389-95. PubMed ID: 9174404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
    Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A.
    Höppner W; Ritter MM
    Hum Mol Genet; 1997 Apr; 6(4):587-90. PubMed ID: 9097963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET proto-oncogene mutations in French MEN 2A and FMTC families.
    Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
    Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
    Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
    Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain.
    Iwashita T; Murakami H; Asai N; Takahashi M
    Hum Mol Genet; 1996 Oct; 5(10):1577-80. PubMed ID: 8894691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells.
    Xing S; Furminger TL; Tong Q; Jhiang SM
    J Biol Chem; 1998 Feb; 273(9):4909-14. PubMed ID: 9478934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.